Floatz logo

Shr-A1811

Urachal Cancer

Sheng ZhangPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

2 Active assets in the Urachal Cancer cohort.

Asset / SponsorPhaseRating
Nivolumab
Instituto do Cancer do Estado de São Paulo
Phase 2CCC
Ivocizumab
Fudan University
Phase 2CCC

Same molecule, other indications

Shr-A1811 is also rated in:

colorectal cancerDormant
BB
Indicative ·
66 / 100
View asset →
breast cancerDormant
BB
Indicative ·
66 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →